Políticas Médicas
Las políticas médicas son documentos que definen el reconocimiento de cubierta para tecnologías, procedimientos y tratamientos. Las declaraciones de necesidad médica en las políticas, sobre si una tecnología, procedimiento, tratamiento, suplido, equipo, medicamento u otro servicio mejora el resultado en la salud de la población para la cual dicha tecnología o tratamiento fue diseñado se basan en evidencia científica, estudios clínicos y opiniones profesionales de nuestros proveedores y de las organizaciones médicas reconocidas.
Cada documento desplegado en este sitio Web se provee con propósitos informativos solamente y no es una autorización, explicación de beneficios o un contrato. El recibir beneficios está sujeto a la satisfacción de todos los términos y condiciones de la cubierta. La tecnología médica cambia constantemente y nos reservamos el derecho de revisar y actualizar nuestras políticas periódicamente.
ID | Título | Última Revisión | Siguiente Revisión | Descripción | Acceso |
---|---|---|---|---|---|
04.002.001 | TRATAMIENTO DEL SINDROME DE TRANSFUSION DE FETO A FETO UTILIZANDO AMNIOREDUCCION Y/O CIRUGIA FETOSCOPICA ASISTIDA POR LASER | Dec 13, 2017 | Policy Archived | Reducción de líquido amniótico y/o terapia de coagulación por ablación con láser se considera para pago... | Ver |
04.002.002 | Fetal Surgery for Prenatally Diagnosed Malformations | Dec 08, 2022 | Policy Archived | Vesicoamniotic shunting as a treatment of urinary tract obstruction may be considered medically necessary in... | Ver |
04.002.004 | GENDER AFFIRMING SURGERY | Oct 24, 2024 | Oct 20, 2025 | Gender affirming surgery is considered medically necessary for the treatment of individuals with gender... | Ver |
04.002.005 | Infertility Treatment | Oct 26, 2023 | Policy Archived | Evaluation and treatment of infertility is considered medicaly necessary and maybe submitted for... | Ver |
05.001.002 | SEVELAMER (REGEL, RENVELA) y FOSRENOL | May 10, 2016 | Policy Archived | Se considera para pago el uso de sevelamer en pacientes de enfermedad renal de último estadío ó diálisis... | Ver |
05.001.004 | Botulinum Toxin | Nov 04, 2024 | Nov 20, 2025 | The use of botulinum toxin may be considered medically necessary for the following:... | Ver |
05.001.005 | Off Label Use of Human Growth Hormone | Nov 14, 2024 | Nov 20, 2025 | Off-label use of recombinant human growth hormone (gh) therapy may be considered medically necessary for... | Ver |
05.001.006 | Recombinant and Autologous Platelet-Derived Growth Factors for Wound Healing and Other NonâOrthopedic Conditions | Feb 12, 2024 | Feb 20, 2025 | Recombinant platelet-derived growth factor (ie, becaplermin) may be considered medically necessary when used... | Ver |
05.001.007 | HEPATITIS-C CRONICA (PEG-INTRON & REBETOL) | May 16, 2016 | Policy Archived | Triple-s cubrirá medicamentos para el tratamiento de infección crónica de hepatitis-c a los asegurados que... | Ver |
05.001.008 | Immunoglobulin Therapy | Dec 05, 2024 | Nov 20, 2025 | Immunoglobulins are derived from human donor plasma and used to treat an array of disorders, including... | Ver |
05.001.009 | Infliximab (Remicade, Inflectra, Renflexis, Avsola and Unbranded Infliximab) | Oct 24, 2024 | Oct 20, 2025 | Infliximab is a tumor necrosis factor (tnf) blocker that may be used and medically necessary for treatment... | Ver |
05.001.010 | Immune Prophylaxis for Respiratory Syncytial Virus | Sep 11, 2024 | Policy Archived | Monthly administration of immune prophylaxis for respiratory syncytial virus (rsv) with palivizumab during... | Ver |
05.001.011 | Acute and Maintenance Tocolysis | Aug 07, 2019 | Policy Archived | Acute tocolytic therapy with calcium channel blockers, magnesium sulfate, prostaglandin inhibitors, and... | Ver |
05.001.012 | (Trastuzumab) Herceptin® | Sep 11, 2024 | Sep 20, 2025 | Trastuzumab may be considered medically necessary for the treatment of patients with breast cancer whose... | Ver |
05.001.014 | Intravenous Anesthetics for the Treatment of Chronic Pain and Psychiatric Disorders | Dec 03, 2024 | Dec 20, 2025 | Intravenous infusion of anesthetics (eg, ketamine or lidocaine) for the treatment of chronic pain, including,... | Ver |
05.001.015 | Advanced Therapies for Pharmacologic Treatment of Pulmonary Hypertension | Dec 20, 2024 | Dec 20, 2025 | Pulmonary arterial hypertension (pah) combination therapy for the treatment of pah (world health... | Ver |
05.001.016 | Uses of Monoclonal Antibodies for the Treatment of Non-Hodgkin Lymphoma | Dec 04, 2024 | Policy Archived | Intravenous rituximab intravenous rituximab (rituxan) may be considered medically necessary to treat... | Ver |
05.001.017 | Bevacizumab | Oct 24, 2024 | Oct 20, 2025 | The use of bevacizumab is considered medically necessary for the following conditions: i. fda-approved... | Ver |
05.001.019 | ABATACEPT (ORENCIA) | Oct 24, 2024 | Oct 20, 2025 | Abatacept is considered for payment in the following indications: adults with rheumatoid arthritis (ra)... | Ver |
05.001.021 | Vandetanib) – Oral Chemotheray | Oct 24, 2025 | Policy Archived | A. vandetanib is considered medically indicated in the treatment of metastatic or unresectable locally... | Ver |